MX2009005148A - Aptamero contra midcina, y uso del mismo. - Google Patents

Aptamero contra midcina, y uso del mismo.

Info

Publication number
MX2009005148A
MX2009005148A MX2009005148A MX2009005148A MX2009005148A MX 2009005148 A MX2009005148 A MX 2009005148A MX 2009005148 A MX2009005148 A MX 2009005148A MX 2009005148 A MX2009005148 A MX 2009005148A MX 2009005148 A MX2009005148 A MX 2009005148A
Authority
MX
Mexico
Prior art keywords
aptamer
against midkine
midkine
substance
inhibitory activity
Prior art date
Application number
MX2009005148A
Other languages
English (en)
Inventor
Shin Miyakawa
Masatoshi Fujiwara
Yoshikazu Nakamura
Takashi Matsui
Sadatoshi Sakuma
Original Assignee
Ribomic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribomic Inc filed Critical Ribomic Inc
Publication of MX2009005148A publication Critical patent/MX2009005148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Abstract

Se provee un aptámero de alta calidad contra midcina; un aptámero que posee una actividad inhibidora contra midcina; un complejo que comprende un aptámero que posee una actividad de unión o actividad inhibidora contra midcina, y una sustancia funcional, por ejemplo, sustancias de afinidad, sustancias para marcación, enzimas, vehículos de suministro de fármacos, fármacos, y similares; un fármaco farmacéutico, inhibidor de la migración celular, reactivo de diagnóstico, agente de marcación, y similares, que comprende un aptámero que posee una actividad de unión o actividad inhibidora contra midcina, o un complejo que comprende el aptámero y una sustancia funcional; un inhibidor de la migración celular, un reactivo de diagnóstico, un agente de marcación, y similares.
MX2009005148A 2006-11-14 2007-11-14 Aptamero contra midcina, y uso del mismo. MX2009005148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006308482 2006-11-14
PCT/JP2007/072099 WO2008059877A1 (fr) 2006-11-14 2007-11-14 Aptamère contre la midkine et son utilisation

Publications (1)

Publication Number Publication Date
MX2009005148A true MX2009005148A (es) 2009-08-24

Family

ID=39401681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005148A MX2009005148A (es) 2006-11-14 2007-11-14 Aptamero contra midcina, y uso del mismo.

Country Status (27)

Country Link
US (1) US8080649B2 (es)
EP (1) EP2096167B1 (es)
JP (1) JP5190573B2 (es)
KR (1) KR101516024B1 (es)
CN (1) CN101573446B (es)
AU (1) AU2007320401B2 (es)
BR (1) BRPI0718913A2 (es)
CA (1) CA2669523C (es)
CO (1) CO6190535A2 (es)
CY (1) CY1113679T1 (es)
DK (1) DK2096167T3 (es)
ES (1) ES2397715T3 (es)
HK (1) HK1135729A1 (es)
HR (1) HRP20130012T1 (es)
IL (1) IL198705A (es)
MX (1) MX2009005148A (es)
MY (1) MY147374A (es)
NO (1) NO342010B1 (es)
NZ (1) NZ577396A (es)
PL (1) PL2096167T3 (es)
PT (1) PT2096167E (es)
RU (1) RU2460794C2 (es)
SI (1) SI2096167T1 (es)
TW (1) TWI481713B (es)
UA (1) UA100847C2 (es)
WO (1) WO2008059877A1 (es)
ZA (1) ZA200903562B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964574B1 (en) 2005-11-14 2016-09-07 Cellmid Limited Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
US10260070B2 (en) 2008-09-24 2019-04-16 Ribomic Inc. Aptamer for NGF and use thereof
JP6041373B2 (ja) * 2010-02-01 2016-12-07 Ｎｅｃソリューションイノベータ株式会社 ＴＮＦ−αに結合するアプタマー分子
EP2551346B1 (en) 2010-03-24 2016-01-27 Ribomic Inc. Aptamer for ngf and use thereof
JP2013545800A (ja) 2010-12-20 2013-12-26 コルゲート・パーモリブ・カンパニー 親水性活性剤、疎水性構造化剤および油担体を含有するゼラチンカプセル化された口腔ケア組成物
HUE039439T2 (hu) * 2011-09-28 2018-12-28 Ribomic Inc NGF aptamer és alkalmazása
JP6020888B2 (ja) * 2012-06-29 2016-11-02 国立大学法人名古屋大学 エポキシエイコサトリエン酸関連疾患の予防又は治療
WO2014080997A1 (ja) 2012-11-21 2014-05-30 株式会社リボミック ミッドカインに対するアプタマー及びその用途
RU2549704C1 (ru) * 2014-03-26 2015-04-27 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Рнк-аптамер, обладающий способностью узнавать характерные для рассеянного склероза аутоантитела
KR102501963B1 (ko) 2016-07-01 2023-02-21 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 변형된 뉴클레오사이드를 포함하는 올리고뉴클레오타이드
KR101985300B1 (ko) * 2016-07-19 2019-06-03 삼성전자주식회사 미드카인 저해제를 포함하는 뇌종양 치료 또는 예방용 약학 조성물
CN109536505B (zh) * 2018-12-07 2021-11-09 暨南大学 鬼臼毒素的核酸适配体及其应用
WO2020124095A1 (en) * 2018-12-14 2020-06-18 Board Of Regents, The University Of Texas System Aka Dna aptamers and use thereof for the treatment of cancer
WO2020241493A1 (ja) * 2019-05-24 2020-12-03 株式会社リボミック 骨形成や骨代謝の異常に関連する疾患の治療薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
JP3842304B2 (ja) 1992-10-08 2006-11-08 喬 村松 癌の診断、治療薬
ATE330620T1 (de) 1997-07-14 2006-07-15 Takashi Muramatsu Verwendung von midkin oder von anti-midkin antikörper
DE69941263D1 (de) 1998-08-24 2009-09-24 Medical Therapies Ltd Zusammensetzungen zur vorbeugung und behandlung der artheriosklerose und der restenose nach ptca
US6858390B2 (en) * 1998-12-31 2005-02-22 Ingeneus Corporation Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes
JP2000354487A (ja) * 1999-06-15 2000-12-26 Takashi Muramatsu ミッドカイン受容体
EP1607102B1 (en) 2003-03-06 2017-01-18 Medical Therapies Limited Preventive for adhesion following abdominal surgery
JP4646070B2 (ja) 2003-03-27 2011-03-09 メディカル セラピーズ リミテッド 関節炎関連遺伝子及びこれの関節炎検査等への利用
JP3940097B2 (ja) * 2003-05-20 2007-07-04 株式会社リボミック 翻訳開始因子ｅＩＦ４Ｅに結合するリガンド
JP2007297282A (ja) 2004-08-13 2007-11-15 Cell Signals Inc 子宮内膜症の発生の際にミッドカインによって起こる影響
JP2006141305A (ja) * 2004-11-22 2006-06-08 Univ Of Tokyo 翻訳開始因子ｅＩＦ４Ｇに結合するリボ核酸
JP2006211905A (ja) * 2005-02-01 2006-08-17 Univ Of Tokyo 腫瘍壊死因子受容体ファミリータンパク質に結合する核酸リガンド
JP2006308482A (ja) 2005-04-28 2006-11-09 Sanyo Electric Co Ltd 検出装置

Also Published As

Publication number Publication date
EP2096167B1 (en) 2012-10-17
NO20092280L (no) 2009-08-14
JP5190573B2 (ja) 2013-04-24
WO2008059877A1 (fr) 2008-05-22
NZ577396A (en) 2011-12-22
PL2096167T3 (pl) 2013-03-29
US20100004432A1 (en) 2010-01-07
IL198705A0 (en) 2011-08-01
AU2007320401A1 (en) 2008-05-22
CY1113679T1 (el) 2016-06-22
BRPI0718913A2 (pt) 2013-12-10
TW200831668A (en) 2008-08-01
RU2009122476A (ru) 2010-12-20
US8080649B2 (en) 2011-12-20
KR20090097879A (ko) 2009-09-16
PT2096167E (pt) 2013-01-25
TWI481713B (zh) 2015-04-21
NO342010B1 (no) 2018-03-12
EP2096167A4 (en) 2009-11-11
CN101573446A (zh) 2009-11-04
CO6190535A2 (es) 2010-08-19
SI2096167T1 (sl) 2013-02-28
EP2096167A1 (en) 2009-09-02
HK1135729A1 (en) 2010-06-11
UA100847C2 (uk) 2013-02-11
DK2096167T3 (da) 2013-02-04
AU2007320401B2 (en) 2012-12-06
ZA200903562B (en) 2010-07-28
MY147374A (en) 2012-11-30
CA2669523A1 (en) 2008-05-22
ES2397715T3 (es) 2013-03-08
RU2460794C2 (ru) 2012-09-10
IL198705A (en) 2014-11-30
CA2669523C (en) 2016-06-21
HRP20130012T1 (hr) 2013-01-31
KR101516024B1 (ko) 2015-04-29
JPWO2008059877A1 (ja) 2010-03-04
CN101573446B (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
MX2009005148A (es) Aptamero contra midcina, y uso del mismo.
WO2007128973A3 (en) Interleukin 1-receptor antagonist composition to treat restenosis
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
PL1935331T3 (pl) Proces przygotowania elektrod modyfikowanych, elektrod przygotowanych przy pomocy tego procesu i biosensory enzymatyczne zawierające takie elektrody
IL192925A0 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
EP2099364B8 (en) Detection of the detachment of immobilized contrast agent in medical imaging applications
EP2099605A4 (en) COMPOSITION AND ARTICLES CONTAINING RETICULATED POLYMER MATRIX AND IMMOBILIZED ACTIVE LIQUID, AND METHODS OF MAKING THE SAME
SG134291A1 (en) Friction body, writing instrument and writing instrument set
WO2011076621A3 (de) Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten
EP2071025A4 (en) PRIMER SET FOR THE REINFORCEMENT OF THE UGT1A1 GENE, REAGENT FOR THE REINFORCEMENT OF THE UGT1A1 GENE THEREFOR AND APPLICATION THEREOF
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
WO2008002449A3 (en) Glycomimetic inhibitors of siglec-8
MX2011013374A (es) Aptamero para quimasa y su uso.
EP2069522A4 (en) LIQUID-CONTAINING ENZYME AND ADMINISTRATION SYSTEM FOR DETECTING ANALYTES ON SURFACES
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
EP2128273A4 (en) PRIMER SET FOR GENE AMPLIFICATION, GENE AMPLIFICATION REAGENT CONTAINING THE SAME, AND USE THEREOF
PT1922415E (pt) Uso de rd9 e is6110 como ácidos nucleicos-alvo para o diagnóstico da tuberculose, e fornecimento de alvos is6110 e rd9 compatíveis com uma utilização multiplex
WO2008008155A3 (en) Small molecule modulators of p53 family signaling
BRPI0919268A8 (pt) Aptâmero que se liga ao ngf e medicamento
EP1939262A4 (en) FASTENING METHOD AND ADHESIVE ADHESIVE FOR USE IN FASTENING
GB0620255D0 (en) Antibody and uses thereof
EP2055775A4 (en) PRIMER ASSEMBLY FOR AMPLIFYING THE CYP2C9 GENE, A REAGENT FOR CYP2C9 GENE AMPLIFICATION, AND USE THEREOF
WO2009017719A8 (en) Modulators of ccr9 receptor and methods of use thereof
WO2008110374A3 (de) Pellets enthaltend pharmazeutische substanz, verfahren zu deren herstellung und deren verwendung

Legal Events

Date Code Title Description
FG Grant or registration